Advertisement Increase Specific Influenza Production - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
More info about

Increase Specific Influenza Production


The vaccine industry is challenged to produce large quantities of vaccines in a rapid and cost-effective way. Major changes to current bioprocesses are both difficult and very expensive to implement.

In an October 2016 webcast, Novo Nordisk Pharmatech hosted a presentation by Aziza Manceur, a research officer at Canada’s National Research Council (NRC).

The National Research Council Canada (NRC) celebrated its 100th anniversary in 2016. It serves both the government and private sectors, working with domestic and
international clients.

Located in Montreal, Aziza presented work performed within the Human Health and Therapeutics Portfolio that includes around 350 people distributed across four different sites. Its role is to help companies develop and commercialise new health technologies.

Download this free case study to find out more.

Quick Contact

Top Products from